Security key
62856X300
Q/C TECHNOLOGIES, INC. - Common Stock, par value $0.001 per share (QCLS)
CUSIP: 62856X300
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 627,555
- Total 13F value
- $2,164,696
- Share change
- -124,266
- SEC-reported price per share
- $3.45
- Number of holders
- 17
- Value change
- -$634,439
- Number of buys
- 9
- Number of sells
- 7
- Shares outstanding
- 11,453,200
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
17
Top holders
10
QCLS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Previous quarter: Q4 2025
Q/C TECHNOLOGIES, INC. SEC filings
Q/C TECHNOLOGIES, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 62856X300
Recent filing periods:
Ownership snapshot
Top reported holders of QCLS - Q/C TECHNOLOGIES, INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
PharmaCyte Biotech, Inc.
Disclosed value leader
PharmaCyte Biotech, Inc.
Comparable rows
15/15
Latest evidence
31 Dec 2025
13D/G
3/4/5
13F
Lead comparable stake: 74%
13D/G row: PharmaCyte Biotech, Inc.
Showing 1-6 of 15 holder rows.
Quick read
PharmaCyte Biotech, Inc. leads the comparable SEC ownership view at 74%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens PharmaCyte Biotech, Inc.'s linked filing trail.
Comparable ownership
Top 5
PharmaCyte Biotech, Inc.
74%
Private Advisor Group, LLC
2.9%
Quinn Opportunity Partners LLC
1.8%
VANGUARD GROUP INC
0.46%
JANE STREET GROUP, LLC
0.35%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| PharmaCyte Biotech, Inc. |
13D/G
3/4/5
10%+ Owner
|
74%
|
$28,646,744
8,475,368 shares
|
$0 | 14 Nov 2025 |
| Private Advisor Group, LLC |
13F
Company
|
2.9%
|
$1,331,966
333,826 shares
|
— | 31 Dec 2025 |
| Quinn Opportunity Partners LLC |
13F
Company
|
1.8%
|
$843,446
211,390 shares
|
— | 31 Dec 2025 |
| VANGUARD GROUP INC |
13F
Company
|
0.46%
|
$211,733
53,066 shares
|
— | 31 Dec 2025 |
| JANE STREET GROUP, LLC |
13F
Company
|
0.35%
|
$161,539
40,486 shares
|
— | 31 Dec 2025 |
| Virtu Financial LLC |
13F
Company
|
0.31%
|
$141,000
35,380 shares
|
— | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
17
Shares
627,555
Rows available
17
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
18
Q1 2026 holders
17
Holder diff
-1
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend